nach oben

Erschienen in:

01.04.2014 | Educational Series—Red Series

Breast cancer management in the elderly

verfasst von: M. Luque, F. Arranz, J. F. Cueva, A. de Juan, P. García-Teijido, L. Calvo, I. Peláez, A. García-Palomo, J. García-Mata, S. Antolín, L. García-Estévez, Y. Fernández

Erschienen in: Clinical and Translational Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The increase in life expectancy in the western world means that we are faced with patients diagnosed with breast cancer in old age with increasing frequency. The management of these cases is a challenge for the oncologist, who must take into account the conditions associated with advanced age and the lack of trials in this population. In this review, we addressed the incorporation of geriatric assessment methods that may be useful in making decisions, the particular biological characteristics of breast cancer in elderly patients and their treatment in both localized and advanced disease. Finally, we collected recommendations based on scientific evidence regarding the monitoring and life-style after finishing treatment.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef

Fulop T, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. Discov Med. 2011;11(61):537–50.PubMed

Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C. The decline in breast cancer mortality in Europe: 2012an update. Breast. 2009;21(1):77–82.CrossRef

Owusu C, Lash TL, Silliman RA. Effect of undertreatment on the disparity in age-related breast cancer-specific survival among older women. Breast Cancer Res Treat. 2007;102(2):227–36.PubMedCrossRef

National Comprehensive Cancer network NCCN Clinical Practice Guidelines in Oncology. Breast Cancer v1.2013. 2013. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed 20 Feb 2013.

Balducci L, Cox CE, Greenberg H, Miguel RV, Karl R, Fabri PJ. Management of cancer in the older aged person. Cancer Control. 1994;1(2):132–7.PubMed

Pal SK, Katheria V, Hurria A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin. 2010;60(2):120–32.PubMedCrossRef

Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224–37.PubMedCrossRef

Lachs MS, Feinstein AR, Cooney LM Jr, Drickamer MA, Marottoli RA, Pannill FC, et al. A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med. 1990;112(9):699–706.PubMedCrossRef

10.

Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92(7):550–6.PubMedCrossRef

11.

Eppenberger-Castori S, Moore DH Jr, Thor AD, Edgerton SM, Kueng W, Eppenberger U, et al. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol. 2002;34(11):1318–30.PubMedCrossRef

12.

Durbecq V, Ameye L, Veys I, Paesmans M, Desmedt C, Sirtaine N, et al. A significant proportion of elderly patients develop hormone-dependant “luminal-B” tumours associated with aggressive characteristics. Crit Rev Oncol Hematol. 2008;67(1):80–92.PubMedCrossRef

13.

Bastiaannet E, Liefers GJ, de Craen AJ, Paesmans M, Desmedt C, Sirtaine N, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat. 2010;124(3):801–7.PubMedCrossRef

14.

Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst. 2000;92(7):550–6.PubMedCrossRef

15.

Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schäfer P, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21(19):3580–7.PubMedCrossRef

16.

Schonberg MA, Marcantonio ER, Ngo L, Li D, Silliman RA, McCarthy EP. Causes of death and relative survival of older women after a breast cancer diagnosis. J Clin Oncol. 2011;29(12):1570–7.PubMedCentralPubMedCrossRef

17.

Audisio RA, Bozzetti F, Gennari R, Jaklitsch MT, Koperna T, Longo WE, et al. The surgical management of elderly cancer patients; recommendations of the SIOG surgical task force. Eur J Cancer. 2004;40(7):926–38.PubMedCrossRef

18.

Cutuli B, Aristei C, Martin C, Perrucci E, Latini P, Quetin P. Breast-conserving therapy for stage I–II breast cancer in elderly women. Int J Radiat Oncol Biol Phys. 2004;60(1):71–6.PubMedCrossRef

19.

Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011;103(14):1101–11.PubMedCentralPubMedCrossRef

20.

Audisio RA, Ramesh H, Longo WE, Zbar AP, Pope D. Preoperative assessment of surgical risk in oncogeriatric patients. Oncologist. 2005;10(4):262–8.PubMedCrossRef

21.

Sandison AJ, Gold DM, Wright P, Jones PA. Breast conservation or mastectomy: treatment choice of women aged 70 years and older. Br J Surg. 1996;83(7):994–6.PubMedCrossRef

22.

Gennari R, Rotmensz N, Perego E, dos Santos G, Veronesi U. Sentinel node biopsy in elderly breast cancer patients. Surg Oncol. 2004;13(4):193–6.PubMedCrossRef

23.

Hieken TJ, Nettnin S, Velasco JM. The value of sentinel lymph node biopsy in elderly breast cancer patients. Am J Surg. 2004;188(4):440–2.PubMedCrossRef

24.

Martelli G, Miceli R, Costa A, Coradini D, Zurrida S, Piromalli D, et al. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study. Cancer. 2008;112(3):481–8.PubMedCrossRef

25.

Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Cancer and Leukemia Group B, Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–7.PubMedCrossRef

26.

International Breast Cancer Study Group, Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006;24(3):337–44.

27.

Mandelblatt JS, Edge SB, Meropol NJ, Senie R, Tsangaris T, Grey L, et al. Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. Cancer. 2002;95(12):2445–54.PubMedCrossRef

28.

Martelli G, Miceli R, Daidone MG, Senie R, Tsangaris T, Grey L, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011;18(1):125–33.PubMedCentralPubMedCrossRef

29.

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.PubMedCrossRef

30.

Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259–65.PubMedCrossRef

31.

START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–107.

32.

Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20.PubMedCrossRef

33.

Kirova YM, Campana F, Savignoni A, Laki F, Muresan M, Dendale R, Institut Curie Breast Cancer Study Group, et al. Breast-conserving treatment in the elderly: long-term results of adjuvant hypofractionated and normofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):76–81.PubMedCrossRef

34.

Hughes KS, Schnaper LA, Cirrincione C, Berry DA, McCormick B, Muss HB, CALGB, ECOG, RTOG, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 or older with early breast cancer. J Clin Oncol. 2010;28(Suppl 15):507.

35.

Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006;98(10):681–90.PubMedCrossRef

36.

Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478–88.PubMedCentralPubMedCrossRef

37.

Smith BD, Haffty BG, Hurria A, Galusha DH, Gross CP. Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol. 2006;24(30):4901–7.PubMedCrossRef

38.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

39.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432–44.

40.

Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750–6.PubMedCrossRef

41.

Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Cancer and Leukemia Group B, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293(9):1073–81.PubMedCrossRef

42.

Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055–65.PubMedCentralPubMedCrossRef

43.

Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–15.PubMedCrossRef

44.

Fargeot P, Bonneterre J, Roché H, Lortholary A, Campone M, Van Praagh I, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol. 2004;22(23):4622–30.PubMedCrossRef

45.

Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27(8):1177–83.PubMedCrossRef

46.

Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92.PubMedCrossRef

47.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–802.PubMedCrossRef

48.

Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, ATAC/LATTE Investigators, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41.PubMedCrossRef

49.

Ring A, Sestak I, Baum M, Howell A, Buzdar A, Dowsett M, et al. Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J Clin Oncol. 2011;29(32):4266–72.PubMedCrossRef

50.

Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008;26(12):1972–9.PubMedCrossRef

51.

Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008;26(12):1956–64.PubMedCrossRef

52.

Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–309.PubMedCrossRef

53.

Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–55.PubMedCrossRef

54.

Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–8.PubMedCentralPubMedCrossRef

55.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, NCIC CTG MAP.3 Study Investigators, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.PubMedCrossRef

56.

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Herceptin Adjuvant (HERA) Trial Study Team, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–44.PubMedCrossRef

57.

Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366–73.PubMedCentralPubMedCrossRef

58.

Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, et al. Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SASBC07)]. Jpn J Clin Oncol. 2011;41(5):709–12.PubMedCrossRef

59.

Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010;21(11):2153–60.PubMedCrossRef

60.

Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, et al. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101–Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer. 2011;11:318.PubMedCentralPubMedCrossRef

61.

Horobin JM, Preece PE, Dewar JA, Wood RA, Cuschieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg. 1991;78(2):213–7.PubMedCrossRef

62.

Robertson JF, Todd JH, Ellis IO, Elston CW, Blamey RW. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ. 1988;297(6647):511–4.PubMedCentralPubMedCrossRef

63.

Fentiman IS, Christiaens MR, Paridaens R, Van Geel A, Rutgers E, Berner J, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer. 2003;39:309–16.PubMedCrossRef

64.

Mustacchi G, Ceccherini R, Milani S, Van Geel A, Rutgers E, Berner J, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003;14:414–20.PubMedCrossRef

65.

Willsher PC, Robertson JFR, Jackson L, al Hilaly M, Blamey RW. Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer. Breast. 1997;6:150–4.CrossRef

66.

Fennessy M, Bates T, MacRae K, Riley D, Houghton J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg. 2004;91:699–704.PubMedCrossRef

67.

Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;(1):CD004272.

68.

Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105(Suppl 1):33–43.PubMedCentralPubMedCrossRef

69.

Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, IMPACT Trialists Group, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–16.PubMedCrossRef

70.

Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–103.PubMedCrossRef

71.

Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–9.PubMedCentralPubMedCrossRef

72.

Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–54.PubMedCrossRef

73.

Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, et al. GEICAM. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069–74.PubMedCrossRef

74.

Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, et al. Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res. 2008;10(5):R77.PubMedCentralPubMedCrossRef

75.

Wilson S, Chia SK. Treatment algorithms for hormone receptor-positive advanced breast cancer. Am Soc Clin Oncol Educ Book. 2013;2013:20–7. doi:E10.1200/EdBook_AM.2013.33.e20.CrossRef

76.

Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664–70.PubMedCrossRef

77.

Vergote I, Faslodex 0020 and 0021 Investigators. Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women. Eur J Cancer. 2002;38(Suppl 6):S57–8.PubMedCrossRef

78.

Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600.PubMedCrossRef

79.

Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–5.PubMedCrossRef

80.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367(5):435–44.PubMedCentralPubMedCrossRef

81.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–9.PubMedCrossRef

82.

Hurria A, Togawa K, Mohile SG, Steger GG, Tonkin K, de Boer RH, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65.PubMedCentralPubMedCrossRef

83.

Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–86.PubMedCrossRef

84.

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–79.PubMedCrossRef

85.

Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15(10):1527–34.PubMedCrossRef

86.

Wildiers H, Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev. 2004;30(4):333–42.PubMedCrossRef

87.

ten Tije AJ, Smorenburg CH, Seynaeve C, Sparreboom A, Schothorst KL, Kerkhofs LG, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer. 2004;40(3):352–7.PubMedCrossRef

88.

Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre L, Mariani L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23(10):2155–61.PubMedCrossRef

89.

Baweja M, Suman VJ, Fitch TR, Mailliard JA, Bernath A, Rowland KM, NCCTG, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or =65 years of age: an NCCTG study. Ann Oncol. 2006;17(4):623–9.PubMedCrossRef

90.

Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012;23(4):897–902.PubMedCrossRef

91.

Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15(2):122–9.PubMedCentralPubMedCrossRef

92.

Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679–86.PubMed

93.

Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, American Society of Clinical Oncology, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24(31):5091–7.PubMedCrossRef

94.

Aebi S, Davidson T, Gruber G, Cardoso F, ESMO Guidelines Working Group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi12–24.

95.

Grunfeld E, Dhesy-Thind S, Levine M, Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update). CMAJ. 2005;172(10):1319–20.PubMedCentralPubMedCrossRef

96.

Rojas MP, Telaro E, Russo A, Fossati R, Confalonieri C, Liberati A. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2000;(4):CD001768.

97.

Schootman M, Jeffe DB, Lian M, Aft R, Gillanders WE. Surveillance mammography and the risk of death among elderly breast cancer patients. Breast Cancer Res Treat. 2008;111(3):489–96.PubMedCrossRef

98.

Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64.PubMedCentralPubMedCrossRef

99.

Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMedCrossRef

100.

Holick CN, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Bersch AJ, Stampfer MJ, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(2):379–86.PubMedCrossRef

Titel: Breast cancer management in the elderly
verfasst von: M. Luque
F. Arranz
J. F. Cueva
A. de Juan
P. García-Teijido
L. Calvo
I. Peláez
A. García-Palomo
J. García-Mata
S. Antolín
L. García-Estévez
Y. Fernández
Publikationsdatum: 01.04.2014
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 4/2014
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1113-2

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Breast cancer management in the elderly

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Identification of microRNAs associated with lymphangiogenesis in human gastric cancer

Obituary

Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy

Comparison of tumor neovasculature-targeted paramagnetic nanoliposomes for MRI in mice xenograft models

CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities

H19 DMR methylation correlates to the progression of esophageal squamous cell carcinoma through IGF2 imprinting pathway

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie